Related Experiment Video
Updated: Jun 2, 2026
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Real-World Efficacy and Safety of Upadacitinib in Korean Patients With Atopic Dermatitis
So Yun Park1, Seok-Jae Heo2, Ho Eun Gwag1
1Department of Dermatology, National Medical Center, Seoul, Korea.
Purpose:
Upadacitinib is an oral selective Janus kinase (JAK) 1 inhibitor that has demonstrated high efficacy in clinical trials for patients with atopic dermatitis (AD). However, clinical trial settings may not always reflect real-world practice. This study aimed to assess the real-world efficacy and safety of upadacitinib in AD patients.
Methods:
One hundred fifteen AD patients treated with upadacitinib were retrospectively analyzed using medical records. Patients who received treatment for at least 16 weeks were included. In the moderate-to-severe AD group, efficacy was assessed by the proportion of patients achieving Eczema Area and Severity Index (EASI) 50, EASI 75, and EASI 90 at weeks 2 and 16 compared to baseline, whereas efficacy in the mild AD group was evaluated based on the reduction in patient-reported outcomes.
Results:
The mean EASI score significantly decreased after 16 weeks of upadacitinib treatment. At week 2, 67%, 35%, and 6% of moderate-to-severe AD patients achieved EASI 50, EASI 75 and EASI 90, respectively. At week 16, 88%, 71%, and 31% of moderate-to-severe AD patients achieved EASI 50, EASI 75 and EASI 90, respectively. Patient-reported outcome measures improved rapidly within 2 weeks and were sustained through week 16. The most common adverse event was acne, occurring in 35 patients (41.2%) with mild severity. No serious adverse events occurred.
Conclusions:
Upadacitinib is effective and safe for AD patients in a real-world clinical setting.
